Previous Close | 6.45 |
Open | 6.51 |
Bid | 5.70 |
Ask | 7.65 |
Strike | 48.00 |
Expire Date | 2024-06-21 |
Day's Range | 6.51 - 6.60 |
Contract Range | N/A |
Volume | |
Open Interest | 1.43k |
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
PRINCETON, N.J., June 13, 2024--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive....
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.